Nuvalent (NUVL) Other Accumulated Expenses (2023 - 2024)
Nuvalent's (NUVL) quarterly Other Accumulated Expenses came in at $1.3 million in Q4 2024, down 21.37% YoY from $1.6 million in Q1 2024, and down 21.37% on a QoQ basis from $1.6 million in Q4 2023.
Powered by 
Analysis
Nuvalent (NUVL) Other Accumulated Expenses (2023 - 2024) Analysis & Trends
Nuvalent (NUVL) has 2 years of Other Accumulated Expenses data on file, last reported at $1.3 million in Q4 2024.
- Quarterly Other Accumulated Expenses fell 21.37% year-over-year to $1.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.3 million (down 21.37% YoY) and the FY2024 annual result came in at $1.3 million, down 21.37% from the prior year.
- Other Accumulated Expenses slipped to $1.3 million in Q4 2024, from $1.6 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.6 million in Q4 2023 to a low of $1.3 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - |